Algenex has more than 20 years’ experience in the veterinary sector and is focused on developing and producing veterinary vaccines using its TopBac® and CrisBio® technology platforms.
We have successfully produced more than 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies and achieved proof-of- concept in more than 20 indications across most livestock species.
The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by the European Medicines Agency (EMA) with potential approval in 2021.
Benefits of using CrisBio® in the production of proteins for veterinary vaccines:
-
Linear scalability
-
Reduced production costs
-
Increased productivity, reaching gram per litre yields
Most advanced projects
RHDV
PCV2
BVD
INFLUENZA
H7N9
African Swine Fever
AB rapid detection test
Partnerships
Algenex has a long track record of successful collaborations with public and private partners on a global scale. Customer satisfaction is one of our top priorities
For us, CrisBio® technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products
DIAGNOSTICS
Algenex has developed the Herdscreen® ASFV Antibody Test for African Swine Fever in collaboration with Global Dx.
Analysis of the new rapid test at the European Union Reference Laboratory for African swine fever (CISA-INIA) showed 100% specificity and higher sensitivity than a commercial ELISA test for the detection of specific antibodies in field and experimental samples from infected animals.
This new pen-side diagnostic test for African Swine Fever will be commercially available in 2020.
